Cover Image
市場調查報告書

緩釋性藥物遞輸市場及開發平台預測

Controlled Release Drug Delivery Market & Pipeline Insight

出版商 KuicK Research 商品編碼 304894
出版日期 內容資訊 英文 830 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
緩釋性藥物遞輸市場及開發平台預測 Controlled Release Drug Delivery Market & Pipeline Insight
出版日期: 2014年05月01日 內容資訊: 英文 830 Pages
簡介

緩釋性藥物遞輸是製劑成分和與藥物以預定比例放出為目的之材料組合的系統。與其他種類的標靶型藥物遞輸比較,為了在預定的時間,及以預定速率順利傳遞,緩釋性藥物遞輸系統更適合。這個系統有二個重要的優點。一個是不需要頻繁給單回數量的藥物,透過零級釋放沒有大幅濃度變動,維持療法上最適合的血漿中藥物濃度。另外能縮短藥物輸送的時間,這樣能改善患者配合度,提高藥物有效性並減少副作用,提高體內的吸收性。隨著社會的高齡化,由於像癌症般的特定疾病的發生增加,使用緩釋性機制的藥物輸送的需求高漲,緩釋性藥物遞輸市場預計今後數年將以年率10%的成長率繼續擴大。

本報告提供緩釋性藥物遞輸市場、臨床實驗開發平台上等待上市的新藥詳查,緩釋性藥物遞輸市場現狀,推動市場成長要素和市場課題等市場動態,今後的市場預測詳細分析。還有臨床實驗開發平台上處於開發階段的緩釋性藥物,已經核准,市售藥物,開發中止的藥物各種詳細研究,市場未來性的預測資料。再加上市場競爭環境與主要企業狀況詳細分析。

第1章 緩釋性藥物遞輸概要

第2章 緩釋性藥物遞輸的機制

第3章 為何需要緩釋性藥物遞輸?

第4章 緩釋性藥物遞輸市場概要

  • 市場概要
  • 臨床實驗開發平台檢驗

第5章 緩釋性藥物遞輸市場動態

  • 推動市場成長要素
  • 課題

第6章 緩釋性藥物遞輸市場未來性

第7章 各階段及各對象疾病之緩釋性藥物臨床實驗開發平台

  • 研究階段
  • 臨床前實驗階段
  • 臨床實驗階段
  • 臨床試驗階段I
  • 臨床試驗階段I/II
  • 臨床試驗階段II
  • 臨床試驗階段II/III
  • 臨床試驗階段III
  • 核准申請
  • 已通過核准

第8章 市售的緩釋性藥物

第9章 開發暫時停止或全面停止的緩釋性藥物

  • 開發無通知
  • 開發停止
  • 開發暫時停止

第10章 市場競爭情形

  • Allergan
  • BioAlliance Pharma
  • Collegium Pharmaceutical
  • Controlled Therapeutics (Ferring Pharmaceuticals)
  • Cosmo Pharmaceuticals
  • Egalet
  • Encore Therapeutics
  • Flamel Technologies
  • GlaxoSmithKline
  • iCeutica
  • Novartis
  • Pfizer
目錄

Controlled drug delivery refers to a system combining the formulation components and devices with the objective of releasing a drug at a predictable rate. The controlled drug delivery system makes it possible in vivo, irrespective of whether the administration of the drug is done through the injected or non-injected route. A controlled drug delivery is observed to occur when a natural or a synthetic polymer is carefully combined with a drug in a manner which enables the release of the active agent from the material in the pre-specified method.

As compared to other forms of targeted drug delivery, the controlled drug delivery system is considered to be more appropriate as it has been successful in delivering the drug at a predetermined rate, locally or systemically for a predetermined period of time. Two major advantages offered by this system include the maintenance of therapeutically optimum drug concentrations in the plasma without major fluctuations through the zero-order release and the absence of the need for frequent single dose administrations. Other advantages include reduced delivery times, which help in improving patient compliance rate, improved levels of clinical efficacy to reduce the side effects and increased bioavailability.

An increase in the proportion of aged people in a society is directly linked to the rising incidence of some specific diseases like cancer, thus relating to the demand for delivery of drugs through the controlled release mechanism. This coupled with increased research activities have led the pharma companies, to focus more on this space, which has in turn become a major driver of this market, thus reflecting the growing need for this technology. Factors like lower dosages, effective administration of drugs, and easy penetration have together made this system a very popular one among the stakeholders. Thus with these drivers pushing the market, it is expected that the controlled drug delivery market would register a growth rate of 10% in the years to come.

The recent breakthroughs in the controlled oral delivery in the field of water-insoluble drugs and biopharmaceuticals are expected to significantly impact the pharmaceutical and biotechnology industries. Additionally, the continuous improvement in the current delivery technologies like novel excipients, processes, and equipment as new tools formulation which scientists could use to develop oral controlled-release formulations has had a significant influence in decreasing cost and increasing the efficiency.

“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:

  • Controlled Release Drug Delivery Market Overview
  • Controlled Release Drug Delivery Mechanism
  • Clinical Pipeline by Phase & Target Indications
  • Drug Profiles in Report: 451
  • Drug Profile in Active Clinical Phase (Research till Registration): 234
  • Majority of Controlled Release Drug in Phase-II Development: 58
  • Marketed Controlled Release Drugs: 140
  • Suspended & Discontinued Drug Profiles

Table of Contents

1. Introduction to Controlled Release Drug Delivery

2. Controlled Release Drug Delivery Mechanism

3. Why Need for Controlled Release Drug Delivery?

4. Controlled Release Drug Delivery Market Overview

  • 4.1 Market Overview
  • 4.2 Clinical Pipeline Insight

5. Controlled Release Drug Delivery Market Dynamics

  • 5.1 Drivers
  • 5.2 Challenges

6. Controlled Release Drug Delivery Market Future Opportunities

7. Controlled Release Drug Clinical Pipeline by Phase & Target Indications

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Clinical
  • 7.4 Phase I
  • 7.5 Phase I/II
  • 7.6 Phase II
  • 7.7 Phase II/III
  • 7.8 Phase III
  • 7.9 Preregistration
  • 7.10 Registered

8. Marketed Controlled Release Drugs

9. Suspended & Discontinued Controlled Release Drug Profiles

  • 9.1 No Development Reported
  • 9.2 Discontinued
  • 9.3 Suspended

10. Competitive Landscape

  • 10.1 Allergan
  • 10.2 BioAlliance Pharma
  • 10.3 Collegium Pharmaceutical
  • 10.4 Controlled Therapeutics (Ferring Pharmaceuticals)
  • 10.5 Cosmo Pharmaceuticals
  • 10.6 Egalet
  • 10.7 Encore Therapeutics
  • 10.8 Flamel Technologies
  • 10.9 GlaxoSmithKline
  • 10.10 iCeutica
  • 10.11 Novartis
  • 10.12 Pfizer

List of Figures

  • Figure 1-1: Oral Drug Delivery Segments
  • Figure 2-1: Types of Controlled Drug Delivery Systems
  • Figure 2-2: Rate Programmed Drug Delivery Systems
  • Figure 2-3: Activation-Modulated Drug Delivery System
  • Figure 4-1: Composition of Drug Delivery Market
  • Figure 4-2: Global Market for Oral Drug Delivery (US$ Billion), 2013 & 2018
  • Figure 4-3: Controlled Release Drug Delivery Clinical Pipeline by Phase (%), 2014
  • Figure 4-4: Controlled Release Drug Delivery Clinical Pipeline by Phase (Number), 2014
  • Figure 4-5: No Development in Controlled Release Drug Delivery Clinical Pipeline by Phase (%), 2014
  • Figure 4-6: No Development in Controlled Release Drug Delivery Clinical Pipeline by Phase (Number), 2014
  • Figure 4-7: Discontinued Controlled Release Drug Delivery Clinical Pipeline by Phase (%), 2014
  • Figure 4-8: Discontinued Controlled Release Drug Delivery Clinical Pipeline by Phase (number), 2014
  • Figure 4-9: Suspended Controlled Release Drug Delivery Clinical Pipeline by Phase (%), 2014
  • Figure 4-10: Suspended Controlled Release Drug Delivery Clinical Pipeline by Phase (Number), 2014
Back to Top